Search | Clinical Trials Finder

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: ORJ-001, Placebo; Drug · Other
Lead sponsor: Oorja Bio, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Doral, Florida • DuBois, Pennsylvania

Conditions: Depression in Adolescence
Interventions: MoodRing App, Usual Care; Device · Other
Lead sponsor: Ana Radovic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Urinary Incontinence
Interventions: OnabotulinumtoxinA; Biological
Lead sponsor: Allergan; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Duarte, California • Encinitas, California • Irvine, California + 21 more

Conditions: Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
Interventions: Fludarabine, Clofarabine, Busulfan, Thymoglobulin, Stem Cell Infusion, Tacrolimus, Methotrexate; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 3 Years to 70 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive, Osteoporosis
Interventions: Vital signs, Urine Pregnancy Test, Questionnaires, Blood Test, Duel-energy X-ray absorptiometry scan, Multi-detector computed tomography, Dual-energy X-ray absorptiometry scan; Diagnostic Test · Other
Lead sponsor: Punam K Saha; Other
Eligibility: 45 Years to 90 Years
Enrollment: 560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Iowa City, Iowa • New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Sansum Closed-Loop Artificial Pancreas, Insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, Safety Health Monitoring System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions: OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo; Drug
Lead sponsor: Oasis Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Developmental Language Disorder
Interventions: Early Achievements - Shaping Early Language and Literacy Skills; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 45 Months to 65 Months
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Attention Deficit Hyperactivity Disorder, Sleep Disturbance
Interventions: Power Down manipulation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 13 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Transfusion, Trauma Coagulopathy, Mortality, Blood Transfusion
Interventions: Not listed
Lead sponsor: Mariah Arif; Government
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Vitamin D Deficiency, HIV
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Reduced Physical Activity
Interventions: Reduced activity; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 60 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: CHW Certification
Interventions: A semester-long course for training of students as CHWs with additional EMPOWER training for delivering a brief trans-diagnostic psychosocial intervention.; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Behavioral Responses to Bright Light Therapy in Elders
Interventions: exposure to bright light, low luminosity red light; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Elizabethtown, Pennsylvania

Conditions: Phobias, Claustrophobia, Social Phobia
Interventions: Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy; Behavioral · Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions: CABA-201 following preconditioning with fludarabine and cyclophosphamide; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 31
States / cities: Orange, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Peridialytic Hypotension
Interventions: Transpulmonary Thermodilution; Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Musculoskeletal Pain
Interventions: Pain Catastrophizing Induction; Behavioral
Lead sponsor: Beth Darnall, PhD; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: carbendazim; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Rectal Cancer, Rectal Adenocarcinoma
Interventions: Lenvatinib, Capecitabine, External Radiation Therapy (XRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
Interventions: Twice daily enoxaparin prophylaxis, Real time dose adjustment; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer, Penile Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Vaginal Squamous Cell Carcinoma, Urethral Squamous Cell Carcinoma
Interventions: EVOLVE104; Drug
Lead sponsor: EvolveImmune United, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 10 more

Search by objective public record fields.

Study of ORJ-001 for the Treatment of IPF

Evaluation of MoodRing on Improving the Quality of Depression Management in Adolescents

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

Early Achievements - Shaping Early Language and Literacy Skills

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD

Trends in Transfusion Strategies and Outcomes in Trauma

Vitamin D in HIV-Infected Patients on HAART

Mechanisms of Skeletal Muscle Insulin Resistance in Older Adults

Train and EMPOWER A Community Health Workforce

Effect of Bright Light Treatment On Elders In a Long Term Care Environment

Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Predicting Hypotension During Dialysis in the ICU

Pain Catastrophizing as a Cause for Systemic Inflammation

Chemotherapy in Treating Patients With Advanced Solid Tumors

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas